The UWCCC proposes to have available for its members Protocol Specific Research support for pilot clinical/translational research studies that would benefit from timely funding. The UWCCC has a long history of funding pilot studies that have led to more timely clinical research and NCI funding. The UWCCC has funded 15 (8 of these ongoing or recently initiated) early phase pilot clinical studies over the last grant period with an accrual of 173 subjects. Efficient accrual to UWCCC-supported studies is enhanced by the UWCCC-supported statewide clinical trials network (Wisconsin Oncology Network). This method of support allows investigators with emerging ideas or promising initial pilot data to apply for the support of a research nurse and data manager to conduct high priority, innovative, feasibility and early stage institutional clinical research protocols. Proposals will be requested twice yearly and will undergo peer-review (under the direction of Associate Directors H. Bailey and P. Sondel) with selection based on scientific merit, need for Protocol Specific Research funding, potential to lead to NCI funding, and UWCCC research priorities. Once selected, protocols receive research nurse/data management support from this mechanism and all the necessary developmental and regulatory support via the Oncore database for UWCCC-required monitoring and reporting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-36
Application #
7809611
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
36
Fiscal Year
2009
Total Cost
$131,689
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Schumacher, Jessica R; Neuman, Heather B; Chang, George J et al. (2018) A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Ann Surg Oncol 25:2587-2595
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506
Liu, Ting; Shi, Changzheng; Duan, Linqi et al. (2018) A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 6:4756-4764
Zhan, Yonghua; Ehlerding, Emily B; Shi, Sixiang et al. (2018) Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. J Biomed Nanotechnol 14:900-909
Bloom, Debra D; Reshetylo, Sofiya; Nytes, Cassandra et al. (2018) Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. J Immunother 41:213-223
Wei, Weijun; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive PET Imaging of T cells. Trends Cancer 4:359-373
Fricke, Stephanie L; Payne, Susan N; Favreau, Peter F et al. (2018) MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol Cancer Ther :
Feld, Shara I; Fan, Jun; Yuan, Ming et al. (2018) Utility of Genetic Testing in Addition to Mammography for Determining Risk of Breast Cancer Depends on Patient Age. AMIA Jt Summits Transl Sci Proc 2017:81-90
Hernández-Santos, Nydiaris; Wiesner, Darin L; Fites, J Scott et al. (2018) Lung Epithelial Cells Coordinate Innate Lymphocytes and Immunity against Pulmonary Fungal Infection. Cell Host Microbe 23:511-522.e5
van Ravesteyn, Nicolien T; van den Broek, Jeroen J; Li, Xiaoxue et al. (2018) Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making 38:126S-139S

Showing the most recent 10 out of 1528 publications